Drug interaction classified as: synergy
Source: DDInter
Antibacterial · Antituberculosis
Cycloserine acts as a structural analog of D-alanine, interfering with bacterial cell wall synthesis. It inhibits two critical enzymes: alanine racemase, which converts L-alanine to D-alanine, and D-alanyl-D-alanine ligase. This dual inhibition prevents the incorporation of D-alanine into the peptidoglycan pentapeptide, thereby disrupting cell wall integrity and leading to bacterial demise, particularly in Mycobacterium tuberculosis.
Manufacturer advises use only if potential benefit outweighs risk—crosses the placenta.
Present in milk—amount too small to be harmful.
Drug interaction classified as: synergy
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Can lead to pyridoxine deficiency and associated neurological disturbances.
Administer pyridoxine (10–50 mg/day) to prevent and treat cycloserine-induced neurological disturbances.
Source: KDT 7e · p916
Additive CNS toxicity
Monitor mood/seizures
Source: Kimi deep-research + Cla
Additive CNS toxicity (seizures, psychosis, peripheral neuropathy).
Monitor for neuropsychiatric symptoms; use pyridoxine supplementation.
Source: Kimi deep-research + Cla
4 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Harrison 22e, Katzung·Verified: 2026-05-10 · House clinical team